Drug Profile
VIB 153
Latest Information Update: 04 Dec 2017
Price :
$50
*
At a glance
- Originator Austin Research Institute; Prima Biomed
- Class Antirheumatics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Nov 2017 Prima BioMed is now called Immutep Limited
- 12 Feb 2002 VIB 153 is available for licensing (http://www.primabiomed.com.au)
- 12 Feb 2002 Preclinical development for Rheumatoid arthritis in Australia (PO)